Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

New treatment strategy for patients with CMT disease on the horizon

A potential new treatment strategy for patients with Charcot-Marie-Tooth disease is on the horizon, thanks to research by neuroscientists now at the University at Buffalo's Hunter James Kelly Research Institute and their colleagues in Italy and England.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

One of the biggest challenges with Alzheimer's disease (AD) is that by the time physicians can detect behavioral changes, the disease has already begun its irreversibly destructive course.

26 Apr 2013

Network of genes is a crucial mechanism driving Late Onset Alzheimer's Disease

Scientists from the Icahn School of Medicine at Mount Sinai, in collaboration with researchers from Icelandic Heart Association, Sage Bionetworks, and other institutions, have discovered that a network of genes involved in the inflammatory response in the brain is a crucial mechanism driving Late Onset Alzheimer's Disease (LOAD).

26 Apr 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

26 Apr 2013

Warning over US neurologist shortage

Neurologists are urging the US Congress to undertake policy changes that will encourage more medical residents to specialize in neurology to ensure patient access to care.

25 Apr 2013

Research reveals that molecular madness goes on in the brain after blast exposure

A multicenter study led by scientists at the University of Pittsburgh School of Medicine shows that mild traumatic brain injury after blast exposure produces inflammation, oxidative stress and gene activation patterns akin to disorders of memory processing such as Alzheimer's disease.

25 Apr 2013

Researchers studying lipids to learn more about normal, abnormal biology

When you have your cholesterol checked, the doctor typically gives you levels of three fats found in the blood: LDL, HDL and triglycerides. But did you know your body contains thousands of other types of fats, or lipids?

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

PPMI to launch additional study to evaluate multiple potential biomarkers for Parkinson's disease

The Parkinson's Progression Markers Initiative, a landmark biomarker clinical study, has completed enrollment of its initial 600-member cohort of Parkinson's patients and controls, and will launch additional study cohorts to leverage the existing PPMI infrastructure and evaluate multiple potential biomarkers for Parkinson's disease.

24 Apr 2013

iQBS researchers discover three unique genetic variations that influence body size, obesity in African ancestry

Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS) and the Center for Genomic Medicine have helped to discover three unique genetic variations that influence body size and obesity in men and women of African ancestry.

23 Apr 2013

Research findings could provide a way to treat onset, progression of Parkinson's disease

The earliest signs of Parkinson's disease can be deceptively mild. The first thing that movie star Michael J. Fox noticed was twitching of the little finger of his left hand.

23 Apr 2013

Taiwan President participates in international memory walk for Alzheimer's disease

Memory Walks are taking place all around the World during World Alzheimer's Month in September every year, to raise awareness about Alzheimer's disease and other dementias.

22 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

A researcher at The Feinstein Institute for Medical Research has discovered additional mechanical properties of articular cartilage, a protective cartilage on the ends of bones that wears down over time, resulting in the development of osteoarthritis.

20 Apr 2013

Alzheimer's Disease News and Research

Further Reading

New treatment strategy for patients with CMT disease on the horizon

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

Network of genes is a crucial mechanism driving Late Onset Alzheimer's Disease

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Warning over US neurologist shortage

Research reveals that molecular madness goes on in the brain after blast exposure

Researchers studying lipids to learn more about normal, abnormal biology

Investigational treatment for ALS passes early phase clinical trial for safety

PPMI to launch additional study to evaluate multiple potential biomarkers for Parkinson's disease

iQBS researchers discover three unique genetic variations that influence body size, obesity in African ancestry

Research findings could provide a way to treat onset, progression of Parkinson's disease

Taiwan President participates in international memory walk for Alzheimer's disease

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

New study shows reduction of dementia risk

Abnormal protein translation leads to Fragile X ataxia, study finds

Excess glutamate drives schizophrenia in high-risk individuals

Tel Aviv University researcher reveals the missing link between brain patterns and Alzheimer's

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News